atrial fibrillation

Summary

Summary: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.

Top Publications

  1. McManus D, Lee J, Maitas O, Esa N, Pidikiti R, Carlucci A, et al. A novel application for the detection of an irregular pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm. 2013;10:315-9 pubmed publisher
    b>Atrial fibrillation (AF) is common and associated with adverse health outcomes. Timely detection of AF can be challenging using traditional diagnostic tools...
  2. Ling T, Wang X, Chai Q, Lau T, Koestler C, Park S, et al. Regulation of the SK3 channel by microRNA-499--potential role in atrial fibrillation. Heart Rhythm. 2013;10:1001-9 pubmed publisher
    MicroRNAs are important regulators of gene expression, including those involving electrical remodeling in atrial fibrillation (AF)...
  3. Qi X, Diness J, Brundel B, Zhou X, Naud P, Wu C, et al. Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog. Circulation. 2014;129:430-40 pubmed publisher
    ..evidence points to functional Ca²⁺-dependent K⁺ (SK) channels in the heart that may govern atrial fibrillation (AF) risk, but the underlying mechanisms are unclear...
  4. Misialek J, Lopez F, Lutsey P, Huxley R, Peacock J, Chen L, et al. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans--Atherosclerosis Risk in Communities (ARIC) study. Circ J. 2013;77:323-9 pubmed
    ..disease (CVD), including ventricular arrhythmias, but the association between serum or dietary Mg and atrial fibrillation (AF) has not been investigated...
  5. Fretts A, Mozaffarian D, Siscovick D, Heckbert S, McKnight B, King I, et al. Associations of plasma phospholipid and dietary alpha linolenic acid with incident atrial fibrillation in older adults: the Cardiovascular Health Study. J Am Heart Assoc. 2013;2:e003814 pubmed publisher
    ..essential n-3 polyunsaturated fatty acid derived from plants and vegetable oils, with incident atrial fibrillation (AF)...
  6. Liu Z, Zhou C, Liu Y, Wang S, Ye P, Miao X, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS ONE. 2012;7:e44906 pubmed publisher
    ..We examined the potential of circulating miRNA to serve as predictors of atrial fibrillation (AF)...
  7. McManus D, Lin H, Tanriverdi K, Quercio M, Yin X, Larson M, et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Heart Rhythm. 2014;11:663-9 pubmed publisher
    MicroRNA (miRNA) expression in atrial tissue has been implicated in pathologic susceptibility to atrial fibrillation (AF). Nevertheless, data on how circulating levels relate to AF are limited...
  8. Lopes C, Pereira T, Barra S. Cardiac resynchronization therapy in patients with atrial fibrillation: a meta-analysis. Rev Port Cardiol. 2014;33:717-25 pubmed
    ..in order to compare the effects of cardiac resynchronization therapy (CRT) in heart failure patients with atrial fibrillation (AF) and in sinus rhythm (SR) and to determine the effect of atrioventricular nodal ablation in AF patients...
  9. Chen L, Sotoodehnia N, Bůžková P, Lopez F, Yee L, Heckbert S, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med. 2013;173:29-35 pubmed publisher
    It is unknown whether atrial fibrillation (AF) is associated with an increased risk of sudden cardiac death (SCD) in the general population. This association was examined in 2 population-based cohorts...

More Information

Publications85

  1. Mira Y, Muhuyati -, Lu W, He P, Liu Z, Yang Y. TGF-β1 signal pathway in the regulation of inflammation in patients with atrial fibrillation. Asian Pac J Trop Med. 2013;6:999-1003 pubmed publisher
    To observe the expression changes of inflammatory markers TGF-β1, Smad3 and IL-6 in patients with atrial fibrillation (AF), and to explore the significance of TGF-β1 signaling pathway in the structural remodeling of AF...
  2. Dublin S, Anderson M, Heckbert S, Hubbard R, Sonnen J, Crane P, et al. Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. J Gerontol A Biol Sci Med Sci. 2014;69:609-15 pubmed publisher
    b>Atrial fibrillation (AF) is associated with higher risk of dementia and Alzheimer's disease. To better understand the mechanism, we examined neuropathologic changes seen with AF.
  3. Piccini J, Sinner M, Greiner M, Hammill B, Fontes J, Daubert J, et al. Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation. 2012;126:2200-7 pubmed publisher
    b>Atrial fibrillation is common among older persons. Catheter ablation is increasingly used in patients for whom medical therapy has failed...
  4. Narayan S, Krummen D, Clopton P, Shivkumar K, Miller J. Direct or coincidental elimination of stable rotors or focal sources may explain successful atrial fibrillation ablation: on-treatment analysis of the CONFIRM trial (Conventional ablation for AF with or without focal impulse and rotor modulation). J Am Coll Cardiol. 2013;62:138-147 pubmed publisher
    This study sought to determine whether ablation of recently described stable atrial fibrillation (AF) sources, either directly by Focal Impulse and Rotor Modulation (FIRM) or coincidentally when anatomic ablation passes through AF ..
  5. Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16:498-506 pubmed publisher
    ..the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation. Secondary objectives related to assessing the cost-effectiveness of new oral anticoagulants stratified by ..
  6. Severino A, Narducci M, Pedicino D, Pazzano V, Giglio A, Biasucci L, et al. Reversible atrial gap junction remodeling during hypoxia/reoxygenation and ischemia: a possible arrhythmogenic substrate for atrial fibrillation. Gen Physiol Biophys. 2012;31:439-48 pubmed publisher
    ..gap-junctions and component connexins (Cx) has been suggested to contribute to the development of atrial fibrillation (AF), including postoperative AF...
  7. Rosenberg M, Samuel M, Thosani A, Zimetbaum P. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin Electrophysiol. 2013;36:328-33 pubmed publisher
    ..ambulatory cardiac rhythm monitoring is a routine part of the management of patients with paroxysmal atrial fibrillation (AF). Current systems are limited by patient convenience and practicality...
  8. Hayashi T, Kumagai K, Naito S, Goto K, Kaseno K, Ohshima S, et al. Preprocedural therapeutic international normalized ratio influence on bleeding complications in atrial fibrillation ablation with continued anticoagulation with warfarin. Circ J. 2013;77:338-44 pubmed
    Safety of atrial fibrillation (AF) ablation in conditions of periprocedural therapeutic international normalized ratio (INR) in combination with heparin is still uncertain, and little is known about the pre-procedural therapeutic INR ..
  9. Voigt N, Heijman J, Wang Q, Chiang D, Li N, Karck M, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129:145-156 pubmed publisher
    Electrical, structural, and Ca2+ -handling remodeling contribute to the perpetuation/progression of atrial fibrillation (AF)...
  10. Oldgren J, Healey J, Ezekowitz M, Commerford P, Avezum A, Pais P, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation. 2014;129:1568-76 pubmed publisher
    b>Atrial fibrillation (AF) is the most common sustained arrhythmia; however, little is known about patients in a primary care setting from high-, middle-, and low-income countries...
  11. Faggioni M, Savio Galimberti E, Venkataraman R, Hwang H, Kannankeril P, Darbar D, et al. Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts. Circ Arrhythm Electrophysiol. 2014;7:313-20 pubmed publisher
    b>Atrial fibrillation (AF) risk has been associated with leaky ryanodine receptor 2 (RyR2) Ca release channels...
  12. Abed H, Wittert G, Leong D, Shirazi M, Bahrami B, Middeldorp M, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-60 pubmed publisher
    Obesity is a risk factor for atrial fibrillation. Whether weight reduction and cardiometabolic risk factor management can reduce the burden of atrial fibrillation is not known...
  13. Zakeri R, Chamberlain A, Roger V, Redfield M. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013;128:1085-93 pubmed publisher
    In patients with heart failure and preserved ejection fraction (HFpEF), atrial fibrillation (AF) may predate, concur with, or develop after HFpEF diagnosis...
  14. Stillitano F, Lonardo G, Giunti G, Del Lungo M, Coppini R, Spinelli V, et al. Chronic atrial fibrillation alters the functional properties of If in the human atrium. J Cardiovasc Electrophysiol. 2013;24:1391-400 pubmed publisher
    ..current (If) is highly modulated in human cardiomyopathies, no definite data exist in chronic atrial fibrillation (cAF). We investigated the expression, function, and modulation of If in human cAF...
  15. Ancona R, Comenale Pinto S, Caso P, Di Salvo G, Severino S, D Andrea A, et al. Two-dimensional atrial systolic strain imaging predicts atrial fibrillation at 4-year follow-up in asymptomatic rheumatic mitral stenosis. J Am Soc Echocardiogr. 2013;26:270-7 pubmed publisher
    ..MS) using two-dimensional (2D) strain (?) and strain rate imaging and its prognostic value in predicting atrial fibrillation (AF) at 4-year follow-up...
  16. Sinner M, Wang N, Fox C, Fontes J, Rienstra M, Magnani J, et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol. 2013;111:219-24 pubmed publisher
    Heart failure, a strong risk factor for atrial fibrillation (AF), is often accompanied by elevated liver transaminases...
  17. Singh S, Micieli A, Wijeysundera H. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. Circulation. 2013;127:2414-23 pubmed publisher
    ..and novel pharmacological therapies are now available to manage stroke risk in patients with nonvalvular atrial fibrillation; however, the cost-effectiveness of LAA occlusion compared with dabigatran and warfarin in patients with ..
  18. Li Y, Jian Z, Yang Z, Chen L, Wang X, Ma R, et al. Increased expression of connective tissue growth factor and transforming growth factor-beta-1 in atrial myocardium of patients with chronic atrial fibrillation. Cardiology. 2013;124:233-40 pubmed publisher
    This study aimed to investigate the roles of connective tissue growth factor (CTGF) and transforming growth factor-?1 (TGF-?1) in atrial fibrosis in patients with chronic atrial fibrillation.
  19. Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114:1483-99 pubmed publisher
    b>Atrial fibrillation (AF) is the most common clinically relevant arrhythmia and is associated with increased morbidity and mortality. The incidence of AF is expected to continue to rise with the aging of the population...
  20. Luo X, Pan Z, Shan H, Xiao J, Sun X, Wang N, et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest. 2013;123:1939-51 pubmed publisher
    b>Atrial fibrillation (AF) is a highly prevalent arrhythmia with pronounced morbidity and mortality...
  21. Fukui A, Takahashi N, Nakada C, Masaki T, Kume O, Shinohara T, et al. Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ Arrhythm Electrophysiol. 2013;6:402-9 pubmed publisher
    We examined the hypothesis that leptin signaling contributes to the atrial fibrosis and atrial fibrillation (AF) evoked by angiotensin II (AngII)...
  22. Ho J, Chang A, Yan B, Yu C, Lam Y, Lee V. Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol. 2012;35:E40-5 pubmed publisher
    Dabigatran is an oral direct thrombin inhibitor recently approved for stroke prevention in atrial fibrillation (AF) as an alternative to warfarin...
  23. Dans A, Connolly S, Wallentin L, Yang S, Nakamya J, Brueckmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634-40 pubmed publisher
    ..110 mg BID was noninferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. In this subgroup analysis, we assess the efficacy and safety of dabigatran in patients who did and did not ..
  24. Calvo N, Brugada J, Sitges M, Mont L. Atrial fibrillation and atrial flutter in athletes. Br J Sports Med. 2012;46 Suppl 1:i37-43 pubmed publisher
    b>Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, with an estimated prevalence of 0.4% to 1% in the general population, increasing with age to 8% in those above 80 years...
  25. Rodríguez Yáñez M, Arias Rivas S, Santamaría Cadavid M, Sobrino T, Castillo J, Blanco M. High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke. Neurology. 2013;81:444-7 pubmed publisher
    ..objective was to determine whether pro-BNP levels in the acute phase of stroke predict the development of atrial fibrillation (AF) in patients with cryptogenic stroke...
  26. Singer D, Hellkamp A, Piccini J, Mahaffey K, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2:e000067 pubmed publisher
    Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy...
  27. Loffredo L, Angelico F, Perri L, Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord. 2012;12:107 pubmed publisher
    b>Atrial fibrillation (AF) is the most common sustained arrhythmia observed in clinical practice. Electrical cardioversion (EC) is commonly used to restore and maintain sinus rhythm but it is characterized by high rate of recurrences...
  28. Mateo J, Rieta J. Radial basis function neural networks applied to efficient QRST cancellation in atrial fibrillation. Comput Biol Med. 2013;43:154-63 pubmed publisher
    The most extended noninvasive technique for medical diagnosis and analysis of atrial fibrillation (AF) relies on the surface elctrocardiogram (ECG)...
  29. Goodman S, Wojdyla D, Piccini J, White H, Paolini J, Nessel C, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63:891-900 pubmed publisher
    This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
  30. Lip G, Lin H, Chien K, Hsu H, Su T, Chen M, et al. Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. Int J Cardiol. 2013;168:414-9 pubmed publisher
    In patients at high risk of stroke, such as atrial fibrillation (AF), there has been great interest in developing stroke risk prediction schemes for identifying those at high risk of stroke...
  31. Gomes T, Mamdani M, Holbrook A, Paterson J, Hellings C, Juurlink D. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ. 2013;185:E121-7 pubmed publisher
    ..objective was to examine incident hemorrhagic events in a large population-based cohort of patients with atrial fibrillation who were starting treatment with warfarin...
  32. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274:461-8 pubmed publisher
    The estimate of 0.4-1.0% prevalence of atrial fibrillation in the most recent American guidelines is based mainly on studies including patients with permanent atrial fibrillation (AF), although recent evidence shows that the stroke risk ..
  33. Kakkar A, Mueller I, Bassand J, Fitzmaurice D, Goldhaber S, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS ONE. 2013;8:e63479 pubmed publisher
    Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk of stroke, from a worldwide perspective...
  34. Smith J, Melander O, Sjögren M, Hedblad B, Engstrom G, Newton Cheh C, et al. Genetic polymorphisms confer risk of atrial fibrillation in patients with heart failure: a population-based study. Eur J Heart Fail. 2013;15:250-7 pubmed publisher
    b>Atrial fibrillation (AF) is a frequent co-morbidity in heart failure (HF) associated with increased mortality, but little is known about the mechanisms underlying AF onset in HF patients...
  35. Yu L, Scherlag B, Li S, Fan Y, Dyer J, Male S, et al. Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve: a noninvasive approach to treat the initial phase of atrial fibrillation. Heart Rhythm. 2013;10:428-35 pubmed publisher
    ..electrical stimulation at the tragus, the anterior protuberance of the outer ear, for inhibiting atrial fibrillation (AF)...
  36. Bruins Slot K, Berge E. Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. JAMA. 2014;311:1150-1 pubmed publisher
    ..the vitamin K antagonist warfarin for preventing strokes or other systemic embolic events in patients with atrial fibrillation? Compared with warfarin, factor Xa inhibitors are associated with a lower risk of stroke and other systemic ..
  37. Shah M, Avgil Tsadok M, Jackevicius C, Essebag V, Eisenberg M, Rahme E, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196-203 pubmed publisher
    Current observational studies on warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation (AF) undergoing dialysis found conflicting results.
  38. Disertori M, Franzosi M, Barlera S, Cosmi F, Quintarelli S, Favero C, et al. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial. BMC Cardiovasc Disord. 2013;13:28 pubmed publisher
    Few data on the thromboembolic (TE) risk of paroxysmal and persistent atrial fibrillation (AF) are available. This study aimed to assess the incidence of TE events in paroxysmal and persistent AF...
  39. Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104 pubmed publisher
    ..The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known...
  40. Kumar S, Haqqani H, Chan M, Lee J, Yudi M, Wong M, et al. Predictive value of impedance changes for real-time contact force measurements during catheter ablation of atrial arrhythmias in humans. Heart Rhythm. 2013;10:962-9 pubmed publisher
    ..Real-time CF, force-time integral, and impedance were measured in 2265 RF lesions for atrial fibrillation or flutter in 34 patients. Operators were blinded to CF measurements...
  41. Kondo Y, Ueda M, Watanabe M, Ishimura M, Kajiyama T, Hashiguchi N, et al. Identification of left atrial ganglionated plexi by dense epicardial mapping as ablation targets for the treatment of concomitant atrial fibrillation. Pacing Clin Electrophysiol. 2013;36:1336-41 pubmed publisher
    Autonomic ganglionated plexi (GPs) play a significant role in the initiation and maintenance of atrial fibrillation (AF). GPs are key targets for a maze procedure...
  42. Gu J, Xu J, Yu H, Yang Y. Novel GATA5 loss-of-function mutations underlie familial atrial fibrillation. Clinics (Sao Paulo). 2012;67:1393-9 pubmed
    This study aimed to identify novel GATA5 mutations that underlie familial atrial fibrillation. A total of 110 unrelated patients with familial atrial fibrillation and 200 unrelated, ethnically matched healthy controls were recruited...
  43. Larsen T, Rasmussen L, Gorst Rasmussen A, Skjøth F, Rosenzweig M, Lane D, et al. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med. 2014;127:329-336.e4 pubmed publisher
    ..provide less protection against myocardial infarction than vitamin K antagonists (VKAs) in patients with atrial fibrillation. This may be particularly evident among "switchers" to dabigatran from VKA, as a result of ..
  44. Hanon O, Assayag P, Belmin J, Collet J, Emeriau J, Fauchier L, et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis. 2013;106:303-23 pubmed publisher
    b>Atrial fibrillation (AF) is a common and serious condition in the elderly. AF affects between 600,000 and one million patients in France, two-thirds of whom are aged above 75 years...
  45. Goren Y, Meiri E, Hogan C, Mitchell H, Lebanony D, Salman N, et al. Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am J Cardiol. 2014;113:976-81 pubmed publisher
    b>Atrial fibrillation (AF) is associated with poor prognosis in patients with heart failure (HF)...
  46. Sairaku A, Yoshida Y, Hirayama H, Nakano Y, Nanasato M, Kamiya H, et al. Clinical significance of sleep-disordered breathing induced by sedatives during ablation of atrial fibrillation. Sleep Med. 2013;14:622-7 pubmed publisher
    Sleep-disordered breathing (SDB) frequently is induced by sedation during ablation of atrial fibrillation (AF). We tested whether or not sedative-induced SDB is associated with clinical sleep apnea syndrome (SAS)...
  47. Brimble K, Ingram A, Eikelboom J, Hart R. Anticoagulants in patients with atrial fibrillation and end-stage renal disease. Postgrad Med. 2012;124:17-25 pubmed publisher
    b>Atrial fibrillation (AF) is a common cardiac arrhythmia and is associated with an increased risk for thromboembolic stroke...
  48. Cangemi R, Pignatelli P, Carnevale R, Corazza G, Pastori D, Farcomeni A, et al. Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. Int J Cardiol. 2013;168:3241-7 pubmed publisher
    Non-valvular atrial fibrillation is associated with an increase in thromboembolism, i.e. stroke, and atherosclerotic events, i.e. myocardial infarction. Vitamin E possesses anti-coagulant as well as anti-atherosclerotic properties...
  49. Kim J, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2013;10:483-9 pubmed publisher
    ..effective as uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFA) of atrial fibrillation (AF)...
  50. Linz D, Hohl M, Nickel A, Mahfoud F, Wagner M, Ewen S, et al. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension. 2013;62:767-74 pubmed publisher
    ..rises and neurohumoral activation potentially involved in the initiation and progression to permanent atrial fibrillation (AF)...
  51. Linhart M, Lewalter T, Mittmann Braun E, Karbach N, Andrié R, Hammerstingl C, et al. Left atrial pressure as predictor for recurrence of atrial fibrillation after pulmonary vein isolation. J Interv Card Electrophysiol. 2013;38:107-14 pubmed publisher
    Identification of reliable risk factors for recurrence of atrial fibrillation (AF) after pulmonary vein isolation (PVI) has important implications...
  52. Nascimento T, Birnie D, Healey J, Verma A, Joza J, Bernier M, et al. Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey. Can J Cardiol. 2014;30:231-6 pubmed publisher
    ..The survey collected data regarding the perioperative management of NOACs in atrial fibrillation patients at high risk for thromboembolism who undergo device implantation...
  53. Nguyen T, Hilmer S, Cumming R. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167:2412-20 pubmed publisher
    b>Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia. In developing countries, AF is a growing public health problem with the epidemiologic transition from communicable to non-communicable diseases...
  54. Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol. 2013;61:463-8 pubmed publisher
    ..was to evaluate the efficacy of polyunsaturated fatty acids (n-3 PUFA) for the prevention of recurrent atrial fibrillation (AF) in patients with normal sinus rhythm...
  55. Abed H, Samuel C, Lau D, Kelly D, Royce S, Alasady M, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm. 2013;10:90-100 pubmed publisher
    Obesity is associated with atrial fibrillation (AF); however, the mechanisms by which it induces AF are unknown. To examine the effect of progressive weight gain on the substrate for AF...
  56. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6:460-6 pubmed publisher
    Pulmonary vein isolation (PVI) for atrial fibrillation is associated with a transient increased risk of thromboembolic and hemorrhagic events...
  57. Zoni Berisso M, Filippi A, Landolina M, Brignoli O, D Ambrosio G, Maglia G, et al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol. 2013;111:705-11 pubmed publisher
    b>Atrial fibrillation (AF) is 1 of the most important healthcare issues and an important cause of healthcare expenditure. AF care requires specific arrhythmologic skills and complex treatment...
  58. Gheorghiade M, Fonarow G, van Veldhuisen D, Cleland J, Butler J, Epstein A, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34:1489-97 pubmed publisher
    Digoxin is recommended for long-term rate control in paroxysmal, persistent, and permanent atrial fibrillation (AF)...
  59. Ganesan A, Kuklik P, Lau D, Brooks A, Baumert M, Lim W, et al. Bipolar electrogram shannon entropy at sites of rotational activation: implications for ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6:48-57 pubmed publisher
    The pivot is critical to rotors postulated to maintain atrial fibrillation (AF)...
  60. Garcia D, Wallentin L, Lopes R, Thomas L, Alexander J, Hylek E, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013;166:549-58 pubmed publisher
    Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may have a higher risk of thrombosis and/or bleeding than VKA-experienced patients...
  61. Guasch E, Benito B, Qi X, Cifelli C, Naud P, Shi Y, et al. Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol. 2013;62:68-77 pubmed publisher
    The goal of this study was to assess mechanisms underlying atrial fibrillation (AF) promotion by exercise training in an animal model. High-level exercise training promotes AF, but the underlying mechanisms are unclear...
  62. Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond). 2013;125:301-9 pubmed publisher
    NAFLD (non-alcoholic fatty liver disease) and AF (atrial fibrillation) are two pathological conditions that are highly prevalent in developed countries and share multiple risk factors...
  63. Xie W, Chang C, Xu Y, Li R, Qu X, Fang W, et al. Prevalence and spectrum of Nkx2.5 mutations associated with idiopathic atrial fibrillation. Clinics (Sao Paulo). 2013;68:777-84 pubmed publisher
    ..5 mutations associated with idiopathic atrial fibrillation (AF)...
  64. Lakkireddy D, Atkins D, Pillarisetti J, Ryschon K, Bommana S, Drisko J, et al. Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation: the YOGA My Heart Study. J Am Coll Cardiol. 2013;61:1177-82 pubmed publisher
    The purpose of this study was to examine the impact of yoga on atrial fibrillation (AF) burden, quality of life (QoL), depression, and anxiety scores. Yoga is known to have significant benefit on cardiovascular health...
  65. Tsadok M, Jackevicius C, Essebag V, Eisenberg M, Rahme E, Humphries K, et al. Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation. 2012;126:2680-7 pubmed publisher
    Stroke is a debilitating condition with an increased risk in patients with atrial fibrillation. Although data from clinical trials suggest that both rate and rhythm control are acceptable approaches with comparable rates of mortality in ..
  66. Ogbonna K, Jeffery S. Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly. Drugs Aging. 2013;30:513-25 pubmed publisher
    ..compare the safety and efficacy of dabigatran, rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older adults. The prevalence and incidence of AF increase with age...
  67. McDowell K, Vadakkumpadan F, Blake R, Blauer J, Plank G, Macleod R, et al. Mechanistic inquiry into the role of tissue remodeling in fibrotic lesions in human atrial fibrillation. Biophys J. 2013;104:2764-73 pubmed publisher
    b>Atrial fibrillation (AF), the most common arrhythmia in humans, is initiated when triggered activity from the pulmonary veins propagates into atrial tissue and degrades into reentrant activity...
  68. Bunch T, May H, Bair T, Weiss J, Crandall B, Osborn J, et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm. 2013;10:1272-7 pubmed publisher
    b>Atrial fibrillation (AF) is a leading cause of total and fatal ischemic stroke...
  69. Lee S, Sahadevan J, Khrestian C, Durand D, Waldo A. High density mapping of atrial fibrillation during vagal nerve stimulation in the canine heart: restudying the Moe hypothesis. J Cardiovasc Electrophysiol. 2013;24:328-35 pubmed publisher
    Moe et al. hypothesized that multiple wavelets (random reentry) were the mechanism of atrial fibrillation (AF) based on studies in a vagal nerve stimulation (VNS) canine model and a computer model of AF, but atrial mapping during AF in ..
  70. Holt T, Hunter T, Gunnarsson C, Khan N, Cload P, Lip G. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract. 2012;62:e710-7 pubmed publisher
    Oral anticoagulants substantially reduce the risk of stroke in atrial fibrillation but are underutilised in current practice...
  71. Dunning J, Nagendran M, Alfieri O, Elia S, Kappetein A, Lockowandt U, et al. Guideline for the surgical treatment of atrial fibrillation. Eur J Cardiothorac Surg. 2013;44:777-91 pubmed publisher
    b>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and its prevalence is ?1-2% of the general population, but higher with increasing age and in patients with concomitant heart disease...
  72. Rasmussen L, Larsen T, Graungaard T, Skjøth F, Lip G. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012;345:e7097 pubmed publisher
    ..against each other, with particular focus on the secondary prevention population for stroke prevention in atrial fibrillation. A secondary objective was to do the same analysis in the primary prevention cohort...
  73. Lakdawalla D, Turakhia M, Jhaveri M, Mozaffari E, Davis P, Bradley L, et al. Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation. J Comp Eff Res. 2013;2:301-12 pubmed publisher
    ..Most high-quality studies used multidrug rate- versus rhythm-control strategies. Assessment of the comparative effectiveness of individual AADs on CV hospitalization and mortality end points is not possible with the current evidence. ..
  74. Guo Y, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, et al. Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. Int J Cardiol. 2013;168:1502-8 pubmed publisher
    Female patients with atrial fibrillation (AF) are at increased risk of stroke. It is unclear what contributes to the gender-related differences in stroke and mortality amongst AF patients...
  75. Turfan M, Erdoğan E, Ertas G, Duran M, Murat S, Celik E, et al. Usefulness of mean platelet volume for predicting stroke risk in atrial fibrillation patients. Blood Coagul Fibrinolysis. 2013;24:55-8 pubmed publisher
    Early detection of atrial fibrillation patients at high risk for stroke is important. There are some studies which indicate that mean platelet volume (MPV) determines the prognosis and risk in patients with a stroke...
  76. Liu Y, Scherlag B, Fan Y, Varma V, Male S, Chaudhry M, et al. Inducibility of atrial fibrillation after GP ablations and "autonomic blockade": evidence for the pathophysiological role of the nonadrenergic and noncholinergic neurotransmitters. J Cardiovasc Electrophysiol. 2013;24:188-95 pubmed publisher
    ..and adrenergic blockade (CAB) as an alternative to ganglionated plexi (GP) ablation to terminate atrial fibrillation (AF) showed mixed results. We investigated the role of other neurotransmitters in AF inducibility...